VYNE Biotech Post Earnings VYNE had a favorable earnings report last week. Fundamentally, analysts predict ( linked)
approximately a doubling of the shart price in the next year. Like many low share priced
biotechnology stocks the price is based on perceived future earnings which can be affected
by favorable FDA process, or well-received research at industry conferences and changing
financials within the company. In general, they have a low beta meaning these stocks are not
general market responsive and run on their own present or future merits.
On the 15-minute chart VYNE was trending down into earnings and the pivoted with a reversal
into the present. The Luxalgo AI "Echo indicator" predicts an upside of 20% in the next two
days before a consolidation period. The "Trendflex" indicator has flipped to postiive and green.
I will take this long trade with a stop loss of $0.15 per share and target of $9.00 over two days
for a 20% ROI and a R:R of 0.15 risk / $ 1.50 reward for a 10:1> Iwill only take biotechology
trades long with a high R:R due to the inheret risk level.
